Pfizer Exercised its Option to License AnTolRx’s Immune Tolerance Therapy for Type 1 Diabetes (T1D)

 Pfizer Exercised its Option to License AnTolRx’s Immune Tolerance Therapy for Type 1 Diabetes (T1D)

Pfizer Exercised its Option to License AnTolRx’s Immune Tolerance Therapy for Type 1 Diabetes (T1D)

Shots:

  • Pfizer to get exclusive rights for development and commercialization of AnTolRx’s lead immunotherapeutic for T1D. AnTolRx to receive upfront, milestones & royalties on sales
  • Under the June 2016 agreement, Pfizer exercised its option to license AnTolRx’s T1D candidate
  • AnTolRx develops antigen-specific therapies, based on immune tolerance induction, for inflammatory and autoimmune diseases including T1D, RA, IBD, and Celiac disease

Click here to read full press release/ article | Ref: AnTolRx | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post